Will Ardelyx’s (ARDX) IBSRELA Data Shift Its Competitive Position In IBS-C Treatments?

Simply Wall St.

Mar 14

Ardelyx recently reported the peer-reviewed publication of pooled clinical data showing its IBSRELA (tenapanor) therapy delivered earlier and sustained symptom relief in adults with IBS-C, with no new...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2619412854"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619412854\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619412854?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-14 14:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619412854","market":"sg","top_or_hot":-1,"title":"Will Ardelyx’s (ARDX) IBSRELA Data Shift Its Competitive Position In IBS-C Treatments?","media":"Simply Wall St.","content":"<div>\n<p>Ardelyx recently reported the peer-reviewed publication of pooled clinical data showing its IBSRELA (tenapanor) therapy delivered earlier and sustained symptom relief in adults with IBS-C, with no new...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/will-ardelyxs-ardx-ibsrela-data-shift-its-competitive-positi\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Ardelyx’s (ARDX) IBSRELA Data Shift Its Competitive Position In IBS-C Treatments?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Ardelyx’s (ARDX) IBSRELA Data Shift Its Competitive Position In IBS-C Treatments?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-14 14:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/will-ardelyxs-ardx-ibsrela-data-shift-its-competitive-positi><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx recently reported the peer-reviewed publication of pooled clinical data showing its IBSRELA (tenapanor) therapy delivered earlier and sustained symptom relief in adults with IBS-C, with no new...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/will-ardelyxs-ardx-ibsrela-data-shift-its-competitive-positi\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/will-ardelyxs-ardx-ibsrela-data-shift-its-competitive-positi","article_id":"2619412854","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/will-ardelyxs-ardx-ibsrela-data-shift-its-competitive-positi","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619412854","pubTimestamp":1773469729,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ardelyx recently reported the peer-reviewed publication of pooled clinical data showing its IBSRELA (tenapanor) therapy delivered earlier and sustained symptom relief in adults with IBS-C, with no new safety concerns identified.\nThe analysis offers clinicians practical guidance on treatment duration and symptom timelines, potentially influencing how IBSRELA is positioned and used in everyday care.\nWe’ll now examine how this new evidence of earlier and sustained IBS-C symptom relief could...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ARDX":"Ardelyx"},"translate_title":"Ardelyx(ARDX)的IBSRELA数据会改变其在IBS-C治疗中的竞争地位吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARDX":1.5},"content_text":"Ardelyx recently reported the peer-reviewed publication of pooled clinical data showing its IBSRELA (tenapanor) therapy delivered earlier and sustained symptom relief in adults with IBS-C, with no new safety concerns identified. The analysis offers clinicians practical guidance on treatment duration and symptom timelines, potentially influencing how IBSRELA is positioned and used in everyday care. We’ll now examine how this new evidence of earlier and sustained IBS-C symptom relief could influence Ardelyx’s existing investment narrative. The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AdvertisementArdelyx Investment Narrative RecapTo own Ardelyx, you need to believe its focused GI and kidney franchise around tenapanor can support growing product adoption while the company manages reimbursement, cost, and balance sheet pressures. The new IBSRELA data publication reinforces the clinical profile and may help prescriber confidence, but it does not materially change the near term spotlight on Medicare access for XPHOZAH and Ardelyx’s path from a US$61.6 million net loss toward sustainable profitability. The recent IBSRELA publication sits alongside Ardelyx’s upcoming appearances at the Leerink Global Healthcare Conference 2026 and the Jefferies Biotech on the Beach Summit, which give management a platform to highlight this new evidence to institutional audiences. How effectively Ardelyx communicates IBSRELA’s earlier and sustained symptom relief story could matter for near term sentiment around IBSRELA guidance of US$410 million to US$430 million in 2026 and investor confidence in execution. Yet while the clinical story around IBSRELA is strengthening, investors should still pay close attention to Ardelyx’s concentrated product risk and evolving payer pressures... Read the full narrative on Ardelyx (it's free!)Ardelyx's narrative projects $704.6 million revenue and $178.8 million earnings by 2028. This requires 22.2% yearly revenue growth and a $235.2 million earnings increase from -$56.4 million today.Uncover how Ardelyx's forecasts yield a $13.50 fair value, a 134% upside to its current price.Exploring Other PerspectivesARDX 1-Year Stock Price Chart Some of the most optimistic analysts were already assuming roughly US$852 million of revenue and over US$300 million of earnings by 2028, so this new IBSRELA data may either reinforce or challenge those expectations depending on how you weigh it against Ardelyx’s concentrated product and pricing risks.Explore 9 other fair value estimates on Ardelyx - why the stock might be worth just $10.00!The Verdict Is YoursDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Ardelyx research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.Our free Ardelyx research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ardelyx's overall financial health at a glance.Ready For A Different Approach?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it. Find the list for free.We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Find 48 companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}